Showing results (171-180 of 355) with videos related to
Sort By:
Pageof 36
Epidemiology and Infection|April 11, 2001
Prevalence of antibodies to hepatitis C virus, HIV and human T-cell leukaemia/lymphoma viruses in injecting drug users in Tayside, Scotland, 1993-7P G McIntyre, D A Hill, K Appleyard, et al.Journal of Medical Virology|July 20, 2004
Hepatitis C virus among self declared non-injecting sexual partners of injecting drug usersK M Roy, D J Goldberg, S Hutchinson, et al.BMJ (Clinical Research Ed.)|May 17, 1997
Molecular investigation into outbreak of HIV in a Scottish prisonD L Yirrell, P Robertson, D J Goldberg, et al.Current Opinion in Pediatrics|August 16, 2020
Prevention of adverse drug effects: a pharmacogenomic approachErika N Scott, Jafar S Hasbullah, Bruce C Carleton, et al.Sexually Transmitted Infections|July 21, 2001
Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotypeM Shahmanesh, H Jaleel, Y DeSilva, et al.Physical Therapy|August 3, 2013
Promoting neuroplasticity for motor rehabilitation after stroke: considering the effects of aerobic exercise and genetic variation on brain-derived neurotrophic factorCameron S Mang, Kristin L Campbell, Colin J D Ross, et al.The Pharmacogenomics Journal|October 26, 2016
The global spectrum of protein-coding pharmacogenomic diversityG E B Wright, B Carleton, M R Hayden, et al.Paediatric Drugs|March 27, 2013
Cancer pharmacogenomics in children: research initiatives and progress to dateShahrad Rod Rassekh, Colin J D Ross, Bruce C Carleton, et al.International Journal of Sports Medicine|October 1, 1989
Muscle carnitine level in endurance training and running a marathonG M Janssen, H R Scholte, M H Vaandrager-Verduin, et al.Bioinformatics (Oxford, England)|June 23, 2018
HUME: large-scale detection of causal genetic factors of adverse drug reactionsMehrdad Mansouri, Bowei Yuan, Colin J D Ross, et al.Pageof 36